Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors

Inclusion Criteria

• •The subject has a histologically confirmed malignancy that is metastatic or unresectable, and for which standard curative or palliative measures do not exist or are no longer effective,
• •The subject has disease that is assessable by tumor marker, physical, or radiologic means,
• •The subject is ≥18 years old,
• •There have been at least 4 weeks since prior chemotherapy or radiation therapy (6 weeks if the last treatment regimen included BCNU or mitomycin C),
• •The subject has an ECOG performance status ≤2 (Karnofsky \>60%),
• •The subject has a life expectancy of ≥3 months,
• •The subject has normal organ and marrow function (hemoglobin \>10g/dL, leukocytes \>3,000/mL, absolute neutrophil count \>1,500/µL, platelets \>100,000/µL, total bilirubin within normal institutional limits of normal,AST (SGOT)/ALT(SGPT) \<2.5 times the upper limit of normal, and creatinine within normal limits,
• •The subject is capable of understanding and complying with the protocol and has signed the informed consent document,
• •Sexually active subjects (both male and female) must use an accepted method of contraception during the course of the study,
• •Female subjects of childbearing potential (pre-menopausal) must have a negative pregnancy test.